LYON, France — A single dose of the chikungunya vaccine IXCHIQ still protects nearly all recipients five years after vaccination, French vaccine maker Valneva SE announced on Tuesday, November 10, 2026, in new long-term data that strengthen the case for the world’s first licensed chikungunya vaccine as outbreaks of the mosquito-borne disease continue to spread across the Americas, Asia and Africa. According to the company, 94 percent of the 221 healthy adults who could be evaluated at the five-year mark still maintained a seroresponse — meaning their blood carried neutralizing antibody levels well above the threshold agreed with regulators — five years after receiving just one shot of IXCHIQ. Illustration: A scientist examines a vial of the chikungunya vaccine in a laboratory, representing the long-term antibody research behind IXCHIQ. What Happened Valneva released the five-year antibody persistence results on November 10, 2026, through a press release distributed by GlobeNew...